N4 Pharma Plc provided an update on its ongoing Australian Research Council grant work with the University of Queensland, investigating the oral delivery of Nuvec® loaded with DNA. The Company has now completed two in vivo studies demonstrating that Nuvec loaded with OVA m-cherry DNA and encapsulated within an acid protective polymer can be dosed orally, penetrate the mucus layer and successfully express the OVA m-cherry locally in the intestine epithelial cells. In the first study Nuvec® was formulated together with the OVA and the whole formulation was coated with the polymer as a capsule.

In the second study the nanoparticles, once loaded with OVA, were individually encapsulated with the polymer and administered via an oral gavage.